文献速递白血病造血干细胞移植与细胞治疗

干扰素α-1b联合IL-2及沙利度胺治疗allo-HSCT后RUNX1::RUNX1T1持续阳性的KIT突变AML一例

[Treatment with interferon α-1b, interleukin-2, and thalidomide for persistent RUNX1::RUNX1T1 in a patient with KIT-mutated acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

本文报道1例64岁伴KIT p.D816V突变的CBF-AML男性患者,阿伐替尼诱导失败后经阿伐替尼联合DCHG方案达CR及流式MRD阴性但融合基因未转阴,桥接9/10相合allo-HSCT后融合基因持续阳性,予以「干白沙」方案(干扰素α-1b、IL-2、沙利度胺)并多次剂量调整,MRD阴性已维持5个月余且耐受良好,提示该方案可能为此类患者提供新选择。

要点

  • 阿伐替尼联合DCHG可使KIT p.D816V突变CBF-AML达CR及流式MRD阴性,但融合基因可仍阳性。
  • allo-HSCT后RUNX1::RUNX1T1持续阳性者可尝试「干白沙」方案并个体化剂量调整。
  • 该方案在本例中MRD阴性维持5个月余,耐受性良好。

核心结论

  • 「干白沙」方案可能为阿伐替尼治疗失败的allo-HSCT术后RUNX1::RUNX1T1融合基因持续阳性的伴KIT p.D816V突变CBF-AML患者提供新治疗手段,且耐受性良好。

研究设计与样本

  • 回顾性分析1例伴KIT p.D816V突变的CBF-AML患者,阿伐替尼诱导治疗失败后桥接allo-HSCT的治疗经过,并进行文献复习。
  • 患者为64岁男性,DA方案诱导未缓解,阿伐替尼联合DCHG方案再诱导达CR及流式MRD阴性,但RUNX1::RUNX1T1融合基因未转阴。

主要发现

  • 巩固治疗期间流式MRD转阳且融合基因水平进行性升高,后行非血缘9/10相合allo-HSCT。
  • 移植后融合基因持续阳性,给予「干白沙」方案治疗,期间先后经历干扰素与IL-2两药联合且剂量增加、泊马度胺加入及常规剂量与增加剂量等调整。
  • 目前MRD阴性已维持5个月余,治疗期间耐受性良好。

临床怎么用

  • 对KIT p.D816V突变CBF-AML患者,阿伐替尼联合DCHG再诱导可达CR及流式MRD阴性但融合基因可能仍阳性。
  • allo-HSCT后RUNX1::RUNX1T1持续阳性者可考虑「干白沙」方案,并按耐受性进行剂量与药物组合调整。

局限性

  • 本文为单例病例报告并文献复习,证据级别有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Here we report the case of a CBF-AML patient with KIT p.D816V mutation who failed avapritinib induction therapy and subsequently underwent bridging allogeneic hematopoietic stem cell transplantation (allo-HSCT), along with a literature review. The patient was a 64-year-old male who did not achieve remission after induction therapy with the DA regimen (Daunorubicin + Cytarabine). After reinduction with avapritinib combined with the DCHG regimen (Decitabine + Homoharringtonine + Cytarabine + Granulocyte colony-stimulating factor), he attained complete remission (CR) and flow cytometry minimal residual disease (MRD) negativity, but the RUNX1::RUNX1T1 fusion gene remained positive. During consolidation therapy, flow MRD reappeared, and the fusion gene level progressively increased. The patient then underwent a 9/10 HLA-matched unrelated donor allo-HSCT. Post-transplant, the fusion gene persisted, prompting treatment with the "ITI" regimen (with dose adjustments, including sequential addition of interferon and interleukin-2, pomalidomide incorporation, and standard vs. escalated dosing of "ITI" regimen). Currently, MRD negativity has been maintained for over 5 months, with good treatment tolerance. This finding suggest that the "ITI" regimen may serve as a novel and well-tolerated therapeutic option for CBF-AML patients with persistent RUNX1::RUNX1T1 fusion gene positivity after allo-HSCT and KIT p.D816V mutation, particularly in cases of avapritinib treatment failure. 回顾性分析1例伴KIT p.D816V突变的核心结合因子相关急性髓系白血病(CBF-AML)患者,阿伐替尼诱导治疗失败后桥接异基因造血干细胞移植(allo-HSCT)的治疗经过,并进行文献复习。患者,男,64岁,DA(柔红霉素+阿糖胞苷)方案诱导治疗未缓解,阿伐替尼联合DCHG(地西他滨+高三尖杉酯碱+阿糖胞苷+G-CSF)方案再次诱导治疗达完全缓解(CR)及流式细胞术微小残留病(MRD)阴性,但患者RUNX1::RUNX1T1融合基因未转阴;在巩固治疗期间,患者流式细胞术MRD转阳及融合基因水平进行性升高,后行非血缘9/10相合allo-HSCT,移植后融合基因持续阳性,后给予干扰素α-1b、白细胞介素2(IL-2)联合沙利度胺(简称"干白沙")方案治疗(期间先后经历干扰素、IL-2两药联合且剂量增加、泊马度胺加入及"干白沙"方案常规剂量及增加剂量等药物调整),目前MRD阴性已维持5个月余,治疗期间耐受性良好。表明"干白沙"方案可为阿伐替尼治疗失败的allo-HSCT术后RUNX1::RUNX1T1融合基因持续阳性的伴KIT p.D816V突变阳性的CBF-AML患者,提供了一种新的治疗手段,且耐受性良好。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Mi RH, Chen L, Wang L, et al. [Treatment with interferon α-1b, interleukin-2, and thalidomide for persistent RUNX1::RUNX1T1 in a patient with KIT-mutated acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a case report and literature review]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 41407465. doi:10.3760/cma.j.cn121090-20250331-00160

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。